USA Today article A year ago, US drug sales topped $1 trillion.

That number dipped to $1.2 trillion last month. 

That’s a drop of 3.6% from April-June. 

“We’re seeing the generic market overtake our brand and brand competition.

The generic market is taking over,” said Robert J. DeBella, vice president of pharmacy sales for Johnson & Johnson. 

DeBella noted that the generic prescription drugs are now the most popular category for generic sales. 

And the new generic competition has started to impact sales of generic drugs, which is good news for the industry, said DeBlla. 

But the problem isn’t just the generic competition. 

According to DeBelly, generic drug sales fell 3.1% last month compared to the same month a year ago. 

It’s not just the cost of the drugs that’s hurting sales.

Drugmakers have been struggling with lower sales and lower profitability. 

In fact, drugmakers reported a drop in sales in April and May. 

So far this year, generic prescriptions have been up 8% year-over-year and sales of new generics have increased 13% to $6.9 trillion. 

The generic market, which accounted for $1 billion in the first half of this year’s year, has now eclipsed the brand and drug-maker markets. 

Drugs that cost $20,000 to $30,000 were up 19% in the same period. 

For years, the generic category has been a major player in the US pharmacy industry.

But in recent years, it has lost ground to the brand-and-drug-maker segment. 

There are now about 9,000 generic medications available for prescription in the United States, according to the U.S. Department of Health and Human Services. 

Brand-and drug-makers make up about 15% of the US pharmaceutical market, according the Centers for Medicare and Medicaid Services.

But this year the generic drug market is up 20%, compared to last year. 

This year, drug companies have been facing competition from generics. 

New drugs from generic companies, such as Mylan, have been gaining market share over generic drugs. 

These generic drugs are usually cheaper, have fewer side effects and are easier to treat, said Andrew Buhler, senior vice president and general manager of research and development at the Eli Lilly &amp: Johnson Co. While the generic drugs from generic manufacturers have taken a bigger share of the market, the drug makers have been able to charge a premium for them. 

As a result, drug makers are having to spend more to produce their drugs.

That could be hurting sales of the generics as well, Buhlers said. 

With that in mind, the Generic Drug Price Index has fallen to an all-time low.

The index, a measure of drug prices for the first quarter of this century, has been below 1,000 since the year 2000. 

About a year and a half ago, generic prescription drug sales were at a record high. 

Now, generics are falling short of their previous record high, which was set in the last two years. 

However, the gap is narrowing. 

Last year, there were 2,634 generics available for purchase.

That was a 15% increase over the year before. 

At the same time, generic sales of brand- and drugmaker drugs were down 9% year over year.

Generic sales of prescription drugs have also been falling since the last time they were above 1,100. 

Since January, generic drugs have dropped 8% in dollar terms, according a report from the Institute for Healthcare Improvement. 

Some of the biggest culprits in this trend are: Generic drug manufacturers are taking a big hit from the rise in generic prescription prices. 

Generic drug makers, such a CVS and Walgreens, are facing stiff competition from brand-name drug makers. 

Pharmaceutical manufacturers are trying to keep prices down. 

Many companies are trying not to raise prices too much. 

Other factors contributing to the decline in generic prescriptions include a slowdown in the growth of the generic industry, slower inflation, and the rise of other generic drugs that can be cheaper and easier to use. 

Buhler pointed out that the U-turn from brand and generic drugs is not the only reason generic prescriptions are down.

“The generic drugs will be a big part of the story.

It will be the first time since 1999 that generic drugs were available for free, and it’s going to be the biggest impact,” he said.

“This year will be different.

Generic prices are going to get very high.” 

The decline in sales of generics has also been blamed on an increase in the number of prescription drug emergency room visits